Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Overview of attention for article published in Journal of Clinical Oncology, June 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog
twitter: 57 X users

patent: 1 patent
guideline: 1 clinical guideline source

Readers on

mendeley: 130 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

CAR immune cells: design principles, resistance and the next generation – Nature

Alert Breaking News - US, 22 Feb 2023

Abramson, J.

Blood test may predict response to CAR T-cell therapy

Healio.com, 28 Sep 2021

September 28, 2021 3 min read Source/Disclosures Published by: Disclosures: Miklos reports consultant/advisory roles with…

Circulating Tumor DNA After Axi-Cel Stratifies Risk, Predicts Outcomes in LBCL

ASH Clinical News, 25 Aug 2021

While many patients with relapsed/refractory large B-cell lymphoma (LBCL) respond to treatment with axicabtagene ciloleucel (axi…

ctDNA Monitoring May Improve Early Relapse Detection in Large B-Cell Lymphoma Following Axi-Cel Treatment

Cancer Network, 23 Jul 2021

Noninvasive circulating tumor DNA (ctDNA) monitoring my be used to assess risk and predict outcomes for patients with large B-cel…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.